TPN parenteral nutrition bags recalled due to lack of sterility
Sentara Infusion Services is recalling 31 TPN bags due to lack of sterility assurance. The recalled bags with Beyond Use Dates December 24–31, 2022, were dispensed nationwide to patients.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of a parenteral medication with lack of sterility assurance—a serious hazard for intravenous use. No illnesses or hospitalizations reported in source text; product meets rubric criterion for High severity as a risk-of-harm product without yet-reported injury.
Plain-English summary
Sentara Infusion Services is recalling TPN (Total Parenteral Nutrition) bags in multiple formulations due to a lack of sterility assurance. The recall involves 31 bags with Beyond Use Dates of December 24–31, 2022.
TPN is a nutritional formula administered directly into the bloodstream or intravenously. Lack of sterility assurance means the products may not have been manufactured under proper sterile conditions and could pose a risk of infection if contaminated.
The recalled products were dispensed nationwide to patients. Patients who received these products should contact their healthcare provider or pharmacy if they have questions about whether their TPN was affected.
The recalled product
- Product
- TPN (a) 115GM/AA, 215GM/DEX, 25GM/LIP 1150ML, (b)90GM/AA, 215GM/DEX, 25GM/LIP 1150ML, (c) TPN AA: 100GM DEX: 105GM 2700ML, (d) TPN AA: 100GM DEX: 105GM LIP: 45GM 2700ML, (e) TPN: AA100GM ; DEX185GM ; LIP50GM IN 1500ML, (f) TPN: AA 150GM ; DEX 220GM ; LIP 45GM IN 2400 ml, (g) TPN
- Manufacturer
- Sentara Infusion Services
- Category
- Drug — Parenteral Nutrition
- Hazard
- sterility-defect
- microbial-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Beyond Use Date: December 24-31
- 2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27